NAGE Q4 2022 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M+18.2% YoY

Gross Profit

$12M57.2% margin

Operating Income

-$1M-6.9% margin

Net Income

-$1M-6.8% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+23.0%

Cash Flow

Operating Cash Flow

-$328,000

Free Cash Flow

-$500,000

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$54M

Total Liabilities

$25M

Stockholders' Equity

$29M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$18M	+18.2%
Gross Profit	$12M	$11M	+10.6%
Operating Income	-$1M	-$5M	+72.8%
Net Income	-$1M	-$5M	+73.4%